Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Biodesix, Inc. (BDSX) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $28,20, with a market capitalisation of $289,10M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,26 to $31,31. This page covers its latest market performance, valuation, price trends and company information.
$289,10M | |
$27,91 | |
$639,80 | |
$3,44 | |
$27,70 | |
266,00 | |
99,47K | |
-- | |
$31,31 | |
$5,26 | |
-- | |
-- |
Biodesix, Inc. (BDSX) is trading at $28,20 in pre-market trading as of 2026-09-16 13:12:00, up 1,80% ($0,50) from the previous close of $27,70
Pre-market trading shows how investors are pricing BDSX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Biodesix, Inc. (BDSX) moved from $26,18 to $28,20, representing a gain of 7,71% ($2,02).
The stock traded between $25,42 and $28,20 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 57,67 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 88,1%
BDSX is currently trading at $28,20, placing it 88,1% of the way from its 52-week low of $5,26 to its 52-week high of $31,31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 334 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Biodesix, Inc. (BDSX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.